Data gathered: January 2
AI Stock Analysis - Zymeworks (ZYME)
Analysis generated May 8, 2024. Powered by Chat GPT.
Zymeworks is a biopharmaceutical company based in Vancouver, Canada, focusing on the development of innovative protein-based therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. As a leader in bi-specific antibodies and other multi-functional therapeutics, the company is advancing a diverse pipeline of product candidates aimed at disrupting the landscape of clinical treatment. Zymeworks prides itself on its proprietary platforms that enable the design of highly-differentiated product candidates.
Stock Alerts - Zymeworks (ZYME)
 |
Zymeworks | December 24 Insider Alert: EcoR1 Capital, LLC is buying shares |
|
Zymeworks | December 19 Price is up by 5.6% in the last 24h. |
|
Zymeworks | December 18 Price is down by -5.5% in the last 24h. |
|
Zymeworks | December 16 Price is up by 6% in the last 24h. |
Alternative Data for Zymeworks
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,417 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,351 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 306 | Sign up | Sign up | Sign up |
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Price | $14.78 |
| Target Price | Sign up |
| Volume | 496,620 |
| Market Cap | $1.01B |
| Year Range | $8.26 - $17.4 |
| Dividend Yield | 0% |
| PE Ratio | 3.56 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Ecor1 Capital, Llc Purchases 16,692 Shares of Zymeworks Inc. (NYSE:ZYME) StockDecember 29 - ETF Daily News |
|
Ecor1 Capital, Llc Acquires 11,958 Shares of Zymeworks Inc. (NYSE:ZYME) StockDecember 29 - ETF Daily News |
|
Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of “Moderate Buy” by BrokeragesDecember 28 - ETF Daily News |
|
Arcturus Therapeutics (NASDAQ:ARCT) vs. Zymeworks (NYSE:ZYME) Head-To-Head ComparisonDecember 27 - ETF Daily News |
 |
Ecor1 capital increases stake in Zymeworks with $1.88 million purchaseDecember 27 - Investing.com |
|
Zymeworks Inc. (NYSE:ZYME) Shares Bought by Fmr LLCDecember 26 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 16M | 14M | 2M | -30M | -33M | -0.390 |
| Q2 '24 | 19M | 16M | 3.6M | -38M | -42M | -0.270 |
| Q1 '24 | 10M | 16M | -6.2M | -32M | -37M | -0.420 |
| Q4 '23 | 16M | 15M | 880,000 | -14M | -23M | -0.200 |
| Q3 '23 | 17M | 17M | -200,000 | -29M | -33M | -0.410 |
Insider Transactions View All
| EcoR1 Capital, LLC filed to buy 14,822,590 shares at $14.5. December 27 '24 |
| EcoR1 Capital, LLC filed to buy 14,720,931 shares at $14.4. December 27 '24 |
| EcoR1 Capital, LLC filed to buy 14,704,239 shares at $14.1. December 27 '24 |
| EcoR1 Capital, LLC filed to buy 14,692,281 shares at $14.3. December 26 '24 |
| EcoR1 Capital, LLC filed to buy 14,440,779 shares at $14.1. December 26 '24 |
Similar companies
Read more about Zymeworks (ZYME) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Zymeworks?
The Market Cap of Zymeworks is $1.01B.
What is Zymeworks' PE Ratio?
As of today, Zymeworks' PE (Price to Earnings) ratio is 3.56.
What is the current stock price of Zymeworks?
Currently, the price of one share of Zymeworks stock is $14.78.
How can I analyze the ZYME stock price chart for investment decisions?
The ZYME stock price chart above provides a comprehensive visual representation of Zymeworks' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Zymeworks shares. Our platform offers an up-to-date ZYME stock price chart, along with technical data analysis and alternative data insights.
Does ZYME offer dividends to its shareholders?
As of our latest update, Zymeworks (ZYME) does not offer dividends to its shareholders. Investors interested in Zymeworks should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Zymeworks?
Some of the similar stocks of Zymeworks are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.